Skip to content
  • Categories
  • Recent
  • Tags
  • Popular
  • Users
  • Groups
Skins
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Collapse
Brand Logo

Forum

  1. Home
  2. Resources
  3. Accelerated Review Options (AROs)
  4. Now Available! Expanded Eligibility for PAAB's Accelerated Review Options (ARO)s
The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB), including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.

Now Available! Expanded Eligibility for PAAB's Accelerated Review Options (ARO)s

Scheduled Pinned Locked Moved Accelerated Review Options (AROs)
1 Posts 1 Posters 6 Views
  • Oldest to Newest
  • Newest to Oldest
  • Most Votes
Reply
  • Reply as topic
Log in to reply
This topic has been deleted. Only users with topic management privileges can see it.
  • D Offline
    D Offline
    danthony
    wrote last edited by
    #1

    Hello @Manufacturer @Agency

    In case you missed it, last week PAAB announced the expansion of eligibility for our Accelerated Review Options (AROs).

    This expansion is designed to meet industry needs head-on. We’ve listened to your feedback and invested in processes that make this possible.

    The following outlines the key changes to the ARO service.

    Historically, ARO was limited to a narrow slice of submission types. As of December 8, 2025 we have flipped the model: ARO is now available for most submissions, with only a few exceptions.

    table for forum.png

    Note: Previously approved content (appropriately shaded) is not considered new content and would not apply to the new content page limits listed above.

    If you'd like your APS assessed for ARO eligibility due to special circumstances (e.g., PAAB has already provided an opinion on the acceptability of a study), please reach out to review@paab.ca for a free assessment

    NEW! Messenger functionality is now included with every ARO until March 31, 2026 at no cost

    We’ve received very positive feedback on the new messenger feature, and early trends show that it effectively contracts time to approval. In advance of our 50th anniversary, we are offering messenger bundled with any ARO review at no additional cost for the end of Q1, 2026.

    To activate messenger, either request it within your initial submission form or email review@paab.ca. This applies to both ongoing and new AROs. Please note that only one package of 5 messages is included as part of this offer.

    Note: Messenger remains available at cost for standard (non-ARO) submissions.

    ARO is now available for DTC submissions
    ARO-2 can now be used for direct-to-consumer (DTC) submissions, provided the submission contains fewer than 10 pages of new content. There are no exclusions applicable to ARO-4.

    Notable ARO fee changes
    • ARO supplemental page fee increase to reflect the more detailed assessments that are now available to ARO:

    • ARO-7 and ARO-10: $2/page → $4/page
    • ARO-2 and ARO-4: $4/page → $8/page

    • Removal of automatic upgrades for short ARO submissions: Previously, APS with ≤2 pages of new content received a free level upgrade. This policy created tracking and reporting challenges. Broader ARO availability would further accentuate these challenges. As such, automatic upgrades have been retired.

    Please reach out below with any questions.
    Thank you
    PAAB Team

    1 Reply Last reply
    0
    Reply
    • Reply as topic
    Log in to reply
    • Oldest to Newest
    • Newest to Oldest
    • Most Votes


    • Login

    • Don't have an account? Register

    • Login or register to search.
    • First post
      Last post
    0
    • Categories
    • Recent
    • Tags
    • Popular
    • Users
    • Groups